title: The FREEDOM trial: in appropriate patients with diabetes and multivessel coronary artery disease, CABG beats PCI.
abstract: The Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial (N Engl J Med 2012; 367:2375-2384) was designed to resolve the long-standing debate over the optimal revascularization strategy in patients with diabetes mellitus and multivessel coronary artery disease. At a median follow-up of 3.8 years, the incidence of the primary outcome (a composite of death, myocardial infarction, and stroke) was significantly lower with bypass surgery than with percutaneous intervention.
authors.affiliation: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Bhuvnesh
authors.initials: B
authors.lastname: Aggarwal
authors.forename: Sachin S
authors.initials: SS
authors.lastname: Goel
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Sabik
authors.forename: Mehdi H
authors.initials: MH
authors.lastname: Shishehbor
mesh_terms: D017130:Angioplasty; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000150:complications* / Q000601:surgery*; D048909:Diabetes Complications / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D016032:Randomized Controlled Trials as Topic; D015607:Stents